|Min SIP Amount||₹500|
|NAV||₹11.96 (07 May 2021)|
|Fund Started||26 Oct 2020|
|Fund Size||₹140 Cr|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||8.9%|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||8.5%|
|Divi's Laboratories Ltd.||Healthcare||Equity||8.1%|
|Johnson & Johnson Ltd.||Diversified||Forgn. Eq||5.0%|
|Apollo Hospitals Enterprise Ltd.||Healthcare||Equity||4.4%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||4.4%|
|Abbott Laboratories||Healthcare||Forgn. Eq||2.4%|
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth is a Equity Mutual Fund Scheme launched by Edelweiss Mutual Fund. This scheme was made available to investors on 26 Oct 2020. Hardik Verma is the Current Fund Manager of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹140 Cr and the Latest NAV as of 07 May 2021 is ₹11.96.
The Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth is rated Very High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000.
The scheme seeks to invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors.